{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Any >/= Grade 3 hematology laboratory abnormality"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Leukocytes (low)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Lymphocytes (low)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Neutrophils (low)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Platelets (low)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"description":"Counts of study participants with post-baseline hematology laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.","groups":[{"description":"Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion","id":"OG000","title":"Brentuximab Vedotin"}],"paramType":"NUMBER","populationDescription":"All participants who received treatment","reportingStatus":"POSTED","timeFrame":"up to 12 months","title":"Hematology Laboratory Abnormalities >/= Grade 3","type":"SECONDARY","unitOfMeasure":"participants"}